cases

Tenet Healthcare Corp. (NYSE: THC)

Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Central District of California on behalf of all persons or entities that purchased the common stock of Tenet Healthcare Corp. (NYSE: THC) between February 28, 2012 and October 3, 2016, inclusive (the “Class Period”).

Close this form
Your name
Mailing address
Contact Information
Shares Purchased
Type of security:Date PurchasedNo. SharesPrice per Share
Shares Sold
Type of security:Date PurchasedNo. SharesPrice per Share

Retention letter:

By submitting this form, you are acknowledging that you have agreed to be represented by Ryan & Maniskas, LLP and such co-counsel as they deem appropriate to associate with in this action.

We have advised you that we have conducted a thorough investigation into the facts and circumstances surrounding the allegations contained in the Complaint, and we believe them to be meritorious. You understand that in seeking to be a plaintiff, you are undertaking certain fiduciary duties and responsibilities, which require you to adequately and fairly represent the class by becoming generally familiar with this litigation so that you can monitor, review and participate with counsel in the prosecution of the action. You may and should confer with us at any time you feel it is appropriate to do so.

Our firm prosecutes class actions and is seeking to undertake this litigation on a contingent fee basis. This means we will not seek payment of any fees unless the lawsuit generates a recovery or benefit for the class. The payment of our fees in this suit is subject to court approval, and we generally seek to have our fees calculated as a percentage of the full amount of the funds recovered, i.e., as a percentage of the amount recovered before the deduction of our fees and expenses.

We will advance all costs and expenses that we deem necessary to pursue an appropriate recovery in this suit. Typical costs and expenses include, but are not limited to, telephone, fax transmission, court costs, computer research, copy, and postage expenses, as well as more substantial items, such as the cost of travel, deposition, trial, mediation expenses, and expert witness and consultant fees. If the lawsuit generates a recovery for the class, we will apply to the Court to have our costs and expenses reimbursed from the settlement fund remaining after the attorneys’ fees have been paid. If there is no recovery, you will not be responsible for any costs.

In the course of the lawsuit, we may, without notice to you, retain and/or work with other law firms, in which case, we would divide any legal fees we receive with such other firms. You agree that we may divide fees with other attorneys for serving as local counsel, or for referral fees, or other services performed. You also agree that with respect to situations in which our co-counsel perform services, they may be entitled to receive between 5% and 10% of our firm’s overall fee. The division of attorneys’ fees with other counsel may be determined upon a percentage basis or upon time spent in assisting the prosecution of the action. The division of fees with other counsel is our sole responsibility and will not increase the fees described above. If we determine at any time that the prosecution of these claims is not feasible or is contrary to justice or the standards of good faith, we are then entitled to withdraw from the representation in the action, with reasonable notice to you. This agreement shall be governed by the laws of the Commonwealth of Pennsylvania. All disputes, disagreements and claims arising out of or related to this agreement shall be resolved exclusively through binding arbitration pursuant to the Rules of the American Arbitration Association.

We look forward to working with you.

Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Central District of California on behalf of all persons or entities that purchased the common stock of Tenet Healthcare Corp. ("Tenet" or the "Company") (NYSE: THC) between February 28, 2012 and October 3, 2016, inclusive (the “Class Period”).

Tenet shareholders may, no later than December 6, 2016, move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Tenet and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/thc.

The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Tenet unlawfully paid kickbacks to induce the referral of patients to Tenet's hospitals for labor and delivery; (2) through this scheme, Tenet deceived the Georgia Medicaid program; and (3) consequently, defendants' statements about Tenet's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On October 3, 2016, the U.S. Department of Justice announced that Tenet and two of its hospitals have agreed to pay more than $513 million and enter guilty pleas to resolve criminal and civil claims accusing the companies of conspiring to defraud the government concerning payments of kickbacks to clinics for referrals of pregnant immigrants, who would falsely be told that Medicaid would cover the cost of childbirth and newborn care only if they delivered at a Tenet hospital.

Under the pleas, the subsidiaries will forfeit $145 million, which is the amount the hospitals netted from Medicare and Medicaid for services provided to patients referred as part of the scheme. Tenet will pay $368 million to settle alleged False Claims Act violations in a whistleblower lawsuit, with the U.S. getting $244 million and the state of Georgia getting most of the remainder.

If you are a member of the class, you may, no later than December 6, 2016, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.